reviewTop 10% cited
Review article: loss of response to anti-TNF treatments in Crohn’s disease
Alimentary Pharmacology & Therapeutics · 2011 · Vol. 33(9) · pp. 987–995
Shomron Ben‐Horin✉(Sheba Medical Center)Yehuda Chowers(Rambam Health Care Campus)
Abstract
Studies defining how best to translate drug-level monitoring and other mechanistic considerations into clinical decisions are urgently needed.
Inflammatory Bowel DiseaseImmunodeficiency and Autoimmune DisordersChronic Lymphocytic Leukemia ResearchMedicineDiscontinuationCrohn's diseaseDiseaseDrug classIncidence (geometry)Watchful waitingInfliximabDrugWeight loss
MeSH terms
Anti-Inflammatory AgentsCrohn DiseaseDose-Response Relationship, DrugHumansImmunologic FactorsTumor Necrosis Factor-alphaTreatment FailureWatchful Waiting
Citations
612
FWCI
11.00
field-weighted impact
References
47
Percentile
99%
vs. same field & year
Citations per year
References
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
Gastroenterology · 2006 · 2,237 citations
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
The American Journal of Gastroenterology · 2009 · 661 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.